Phenazocine

Revision as of 17:46, 8 April 2015 by Aparna Vuppala (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Phenazocine
Clinical data
SynonymsFenazocina, Phenazocinum, DEA No. 9715
Routes of
administration
Oral
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC22H27NO
Molar mass321.45588 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Phenazocine

Articles

Most recent articles on Phenazocine

Most cited articles on Phenazocine

Review articles on Phenazocine

Articles on Phenazocine in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Phenazocine

Images of Phenazocine

Photos of Phenazocine

Podcasts & MP3s on Phenazocine

Videos on Phenazocine

Evidence Based Medicine

Cochrane Collaboration on Phenazocine

Bandolier on Phenazocine

TRIP on Phenazocine

Clinical Trials

Ongoing Trials on Phenazocine at Clinical Trials.gov

Trial results on Phenazocine

Clinical Trials on Phenazocine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Phenazocine

NICE Guidance on Phenazocine

NHS PRODIGY Guidance

FDA on Phenazocine

CDC on Phenazocine

Books

Books on Phenazocine

News

Phenazocine in the news

Be alerted to news on Phenazocine

News trends on Phenazocine

Commentary

Blogs on Phenazocine

Definitions

Definitions of Phenazocine

Patient Resources / Community

Patient resources on Phenazocine

Discussion groups on Phenazocine

Patient Handouts on Phenazocine

Directions to Hospitals Treating Phenazocine

Risk calculators and risk factors for Phenazocine

Healthcare Provider Resources

Symptoms of Phenazocine

Causes & Risk Factors for Phenazocine

Diagnostic studies for Phenazocine

Treatment of Phenazocine

Continuing Medical Education (CME)

CME Programs on Phenazocine

International

Phenazocine en Espanol

Phenazocine en Francais

Business

Phenazocine in the Marketplace

Patents on Phenazocine

Experimental / Informatics

List of terms related to Phenazocine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Phenazocine (brand names Prinadol, Narphen) is an opioid analgesic drug, which is related to pentazocine and has a similar profile of effects.

Effects of phenazocine include analgesia and euphoria, also may include dysphoria and hallucinations at high doses, most likely due to action at κ-opioid and σ receptors.[1]

Phenazocine appears to be a much stronger analgesic with fewer side effects than pentazocine, probably due to a more favorable μ/κ binding ratio. Phenazocine is a much more potent analgesic than pentazocine and other drugs in the benzomorphan series, most probably due to the presence of an N-phenethyl substitution, which is known to boost μ-opioid activity in many classes of opioid analgesics.[2]

Consequently phenazocine is some 4x the potency of morphine as an analgesic. Also it does not cause spasm of the sphincter of Oddi, making it more suitable than morphine for the treatment of biliary or pancreatic pain.[3]

History

Phenazocine was invented in the 1950s.[4][5] It was one of a number of benzomorphan opioids (including pentazocine, dezocine, and cyclazocine) developed in the search for non-addictive strong analgesics.

Phenazocine was once widely used, and was mainly supplied as 5 mg tablets of the hydrobromide salt for sublingual use (Narphen, Prinadol and other names), but its use was discontinued in the United Kingdom in 2001.[6]

Phenazocine was briefly used in the United States but fell out of favour for the above-mentioned reasons;Template:Which[citation needed] it remains a Schedule II substance under the Comprehensive Drug Abuse Control & Prevention Act (aka Controlled Substances Act) of 1970 (CSA) but is not manufactured; other Schedule II narcotics not in use in the United States include bezitramide and metopon. The DEA ACSCN for phenazocine is 9715 and its 2013 annual manufacturing quota was 6 grammes [7]

References

  1. Harris LS, Pierson AK (February 1964). "Some Narcotic Antagonists in the Benzomorphan Series". Journal of Pharmacology and Experimental Therapeutics. 143: 141–8. PMID 14163985.
  2. Feinberg AP, Creese I, Snyder SH (November 1976). "The opiate receptor: a model explaining structure-activity relationships of opiate agonists and antagonists". Proceedings of the National Academy of Sciences USA. 73 (11): 4215–9. doi:10.1073/pnas.73.11.4215. PMC 431391. PMID 186791.
  3. Hopton D. (January 1971). "Double-blind clinical trial of the analgesic effects of phenazocine hydrobromide (Narphen) compared with morphine sulphate in patients with acute abdominal pain". Gut. 12 (1): 51–4. doi:10.1136/gut.12.1.51. PMC 1411461. PMID 4929685.
  4. Clarke EG (August 8, 1959). "Identification of Phenazocine, a Potent New Analgesic". Nature. 184 (Suppl 7): 451–451. doi:10.1038/184451a0. PMID 13810504.
  5. Eckenhoff JE (May–June 1959). "Phenazocine, a new benzomorphan narcotic analgesic". Anesthesiology. 20 (3): 355–8. doi:10.1097/00000542-195905000-00016. PMID 13650222.
  6. "Monthly Release Terming and Coding Newsletter" (PDF). NHS Information Authority. February 2001. Retrieved 2008-01-11.[dead link]
  7. http://www.deadiversion.usdoj.gov/fed_regs/quotas/2013/fr0620.htm